LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and thera...
LipidBrick® IM21.7c cationic lipids offer new possibilities in LNP engineering for RNA therapeutics and its Impact of a novel cationic lipid on both mRNA, LNP properties and in vivo biodistribution.
In this webinar Dr. Malik Hellal , Dr. Claire Guéguen and Dr. Julien Dépollier will present how Polyplus developed LipidBrick® IM21.7c to overcome current limitations of ionizable lipids by enabling a wider in vivo biodistribution and decreasing accumulation in the liver. LipidBrick® IM21.7c aims to to improve LNP formulation to meet the growing demand of the mRNA therapeutic market.
Learn more about how novel cationic lipid can address current challenges for mRNA therapeutics:
- Improves efficiency of LNPs
- Improves biodistribution of LNPs to broaden their use
- Ensures drug and patient safety with improved particle stability